title: Antitumour effect of cyclin-dependent kinase inhibitors (p16(INK4A), p18(INK4C), p19(INK4D), p21(WAF1/CIP1) and p27(KIP1)) on malignant glioma cells.
abstract: Cyclin-dependent kinase inhibitors (CDKIs) are considered as novel anticancer agents because of their ability to induce growth arrest or apoptosis in tumour cells. It has not yet been fully determined, however, which CDKI is the best candidate for the treatment of malignant gliomas and whether normal brain tissues are affected by CDKI expression. Using recombinant adenoviral vectors that express CDKIs (p16(INK4A), p18(INK4C), p19(INK4D), p21(WAF1/CIP1) and p27(KIP1)), we compared the antitumour effect of CDKIs on malignant glioma cell lines (A172, GB-1, T98G, U87-MG, U251-MG and U373-MG). p27(KIP1) showed higher ability to suppress the growth of all tumour cells tested than other CDKIs. Interestingly, overexpression of p27(KIP1) induced autophagic cell death, but not apoptosis in tumour cells. On the other hand, p27(KIP1) overexpression did not inhibit the viability of cultured astrocytes (RNB) nor induced autophagy. Overall, our findings suggest that gene transfer of p27(KIP1) may be a promising approach for the therapy of malignant gliomas.
authors.affiliation: Department of Neurosurgery, Mount Sinai School of Medicine, New York, NY 10029, USA.
authors.forename: T
authors.initials: T
authors.lastname: Komata
authors.forename: T
authors.initials: T
authors.lastname: Kanzawa
authors.forename: H
authors.initials: H
authors.lastname: Takeuchi
authors.forename: I M
authors.initials: IM
authors.lastname: Germano
authors.forename: M
authors.initials: M
authors.lastname: Schreiber
authors.forename: Y
authors.initials: Y
authors.lastname: Kondo
authors.forename: S
authors.initials: S
authors.lastname: Kondo
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use; D018797:Cell Cycle Proteins / Q000037:antagonists & inhibitors* / Q000302:isolation & purification*; D045744:Cell Line, Tumor; D019941:Cyclin-Dependent Kinase Inhibitor p16 / Q000037:antagonists & inhibitors*; D050764:Cyclin-Dependent Kinase Inhibitor p19; D050759:Cyclin-Dependent Kinase Inhibitor p21; D050760:Cyclin-Dependent Kinase Inhibitor p27; D018844:Cyclin-Dependent Kinases / Q000037:antagonists & inhibitors*; D016213:Cyclins / Q000302:isolation & purification*; D004791:Enzyme Inhibitors / Q000627:therapeutic use*; D005910:Glioma / Q000473:pathology*; D006801:Humans; D025521:Tumor Suppressor Proteins / Q000302:isolation & purification*
chemical_list: D000970:Antineoplastic Agents; C493956:CDKN1A protein, human; C493974:CDKN2D protein, human; D018797:Cell Cycle Proteins; D019941:Cyclin-Dependent Kinase Inhibitor p16; D050764:Cyclin-Dependent Kinase Inhibitor p19; D050759:Cyclin-Dependent Kinase Inhibitor p21; D016213:Cyclins; D004791:Enzyme Inhibitors; D025521:Tumor Suppressor Proteins; D050760:Cyclin-Dependent Kinase Inhibitor p27; D018844:Cyclin-Dependent Kinases